Author:
Imblum Brittney A.,Baloch Zubair W.,Fraker Douglas,LiVolsi Virginia A.
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology,General Medicine,Endocrinology, Diabetes and Metabolism,Pathology and Forensic Medicine
Reference16 articles.
1. Rossi, E., Sgambato, A., De Chiara, G., Ciardiello, F., & Gridelli, C. (2016). Thyroid-Induced Toxicity of Check-Point Inhibitors Immunotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer. Journal of Endocrinology and Diabetes, 3(1): 1–10.
2. Orlov, S., Salari, f., Kashat, L., & Walfish, P. Induction of Painless Thyroiditis in Patients Receiving Programmed Death 1 Receptor Immunotherapy for Metastatic Malignancies. (2015). J Clin Endocrinol Metab, 100(5): 1738–1741.
3. Kwok, G., Yau, T., Chiu, J., Tse, E., & Kwong, Y. Pembrolizumab (Keytruda). (2016). Human Vaccines & Immunotherapeutics, 12(11): 2777–2789.
4. Chowdhury, S., Veyhl, J., Jessa, F., Polyakova, O., Alenzi, A., MacMillan, C., Ralhan, R., & Walfish, P. Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants. (2016). Oncotarget, 7(22): 31318–32328.
5. Filette, J., Jansen, Y., Schreuer, M., Hendrik, E., Velkeniers, B., Neyns, B., & Bravenboer, B. (2016). Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated with Pembrolizumab. J Clin Endocrinol Metab, 101(11): 4431–4439.
Cited by
28 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献